68Ga-XACP3 PET/CT in Prostate Cancer

This study is evaluating a new imaging agent called 68Ga-XACP3 used in PET/CT scans (a type of nuclear imaging) to detect prostate cancer — including new cases, recurrent disease, and metastases — and comparing it to the current standard imaging agent (68Ga-PSMA). **You may be eligible if...** - You are 18 years or older with a diagnosis of prostate cancer (newly diagnosed, suspected recurrence, or with known metastases) - You are already scheduled for a standard 68Ga-PSMA PET/CT scan as part of your care - You can provide informed consent **You may NOT be eligible if...** - You or your legal representative are unable or unwilling to give written informed consent Talk to your doctor to see if this trial is right for you.